ACC 24: Empagliflozin remains competitive therapy in HF market despite EMPACT-MI trial outcome, says GlobalData
At the American College of Cardiology’s (ACC) 73rd Annual Scientific Session, the results of Eli Lilly and Boehringer Ingelheim’s Phase III EMPACT-MI trial, which examined...